LEADER 04854nam 2201345z- 450 001 9910580205403321 005 20231214133149.0 035 $a(CKB)5690000000012034 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/87472 035 $a(EXLCZ)995690000000012034 100 $a20202207d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aImmunotherapy, Tumor Microenvironment and Survival Signaling 210 $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 electronic resource (376 p.) 311 $a3-0365-4419-4 311 $a3-0365-4420-8 330 $aThe book is based on the Cancers journal Special Issue entitled ?Immunotherapy, Tumor Microenvironment and Survival Signaling", and focuses on important problems concerning tumors and tumor microenvironment interactions, as well as novel immunotherapies such as CAR-T cell therapy. Immunotherapies have recently shown remarkable results in the treatment of cancer patients. However, there are still many questions that remain to be solved in regards to more effective therapies, such as the tumor heterogeneous profile, tumor microenvironment, and tumor survival epigenetic and genetic pathways, all of which make patients resistant to the presently available treatments for cancer. This book demonstrates different approaches to overcome the challenges faced by immunotherapies due to suppressive tumor microenvironments. This book includes 18 papers that can be divided into three chapters: 1. novel immunotherapies; 2. targeting tumor microenvironment and novel approaches; 3. targeting tumors and tumor microenvironment in different types of cancer. 606 $aMedicine$2bicssc 606 $aClinical & internal medicine$2bicssc 610 $aAutophagy 610 $acolorectal cancer 610 $aimmunotherapy 610 $atumor stroma 610 $atumor microenvironment 610 $aimmune checkpoint inhibitors 610 $achemotherapy 610 $atyrosine kinase inhibitors 610 $aangiogenesis 610 $acheck point inhibitors 610 $aprogrammed cell death protein 1 610 $aprogrammed cell death 1 ligand 1 610 $acardiotoxicity 610 $alung metastasis 610 $aCAR-T 610 $ahypoxia 610 $atumor 610 $amicroenvironment 610 $aCD19 610 $aBCMA 610 $acancer 610 $amelanoma 610 $aimmune escape 610 $aantigen loss 610 $achimeric antigen receptor 610 $aelectroporation 610 $alentivirus 610 $alentiviral transduction 610 $amacrophages 610 $aleukemia cells 610 $alytic peptides 610 $atargeted therapy 610 $adendritic cells 610 $apathogenesis 610 $arisk factors 610 $abreast cancer 610 $aresistance 610 $acheckpoint 610 $atargeted treatment 610 $apersonalized medicine 610 $apediatric solid tumors 610 $achimeric antigen receptors 610 $acancer vaccines 610 $aoncolytic viral therapy 610 $aimmunomodulation 610 $aDCLK1 610 $atumor stem cells 610 $aclonogenicity 610 $amitochondria 610 $amitochondrial transfer 610 $atunneling nanotubes 610 $atriple-negative breast cancer 610 $aimmune checkpoint inhibitor 610 $acombination therapy 610 $acancer nanomedicine 610 $atumor antigens 610 $acancer metabolism 610 $acancer immunotherapy 610 $ananoparticles 610 $aimmunotherapeutic agent 610 $aimmunomodulators 610 $atuft cells 610 $acancer stem cells 610 $aimmunotherapies 610 $amyeloid-derived suppressor cells 610 $aregulatory T cells 610 $acrosstalk 610 $atumor immune evasion 610 $acell-cell contact 610 $a?2 integrins 610 $aCD18 610 $aCD11 610 $aCAR-T cells 610 $aCD37 610 $acell therapy 610 $atumor antigen 610 $alymphoma 610 $aCAR macrophage 610 $aCAR T cell 610 $asolid tumors 610 $aimmunometabolism 610 $amiRNA 610 $aimmunogenic cell death 615 7$aMedicine 615 7$aClinical & internal medicine 700 $aGolubovskaya$b Vita$4edt$01304516 702 $aGolubovskaya$b Vita$4oth 906 $aBOOK 912 $a9910580205403321 996 $aImmunotherapy, Tumor Microenvironment and Survival Signaling$93027516 997 $aUNINA